[血浆凝块回缩实验方法研究]。

Yang-Gan Luo, Zi-Han Lu, Han-Jing Liao, Dou-Dou Hao, Man-Jing Huang, Zhi-Xiang Zhu
{"title":"[血浆凝块回缩实验方法研究]。","authors":"Yang-Gan Luo, Zi-Han Lu, Han-Jing Liao, Dou-Dou Hao, Man-Jing Huang, Zhi-Xiang Zhu","doi":"10.19746/j.cnki.issn.1009-2137.2024.04.045","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To explore the key factors affecting plasma clot retraction and optimize the experimental method of plasma clot retraction, in order to study the regulation of platelet function and evaluate the modulatory effects of drugs on plasma clot retraction.</p><p><strong>Methods: </strong>The effects of different concentrations of thrombin, Ca2 <sup>+</sup> and platelets on plasma clot retraction were studied, and the detection system of plasma clot retraction was optimized. The availability of the detection system was then validated by analyzing the regulatory effects of multiple signaling pathway inhibitors on plasma clot retraction.</p><p><strong>Results: </strong>Through the optimization study of multiple factors, platelet rich plasma (PRP) containing 0.5 mmol/L Ca2 <sup>+</sup> and 40×10<sup>9</sup>/L platelets was treated with 0.2 U/ml thrombin to perform plasma clot retraction analysis. After treatment with thrombin for 15 min, plasma clot retracted significantly. After treatment with thrombin for 30 min, the percentage of plasma clot retraction was more than 50%. The regulatory effects of multiple signaling pathway inhibitors on plasma clot retraction were studied in this detection system. PKC inhibitor Go 6983 exhibited a significant inhibitory effect on plasma clot retraction, while PI3K inhibitor Ly294002 and p38 MAPK inhibitor SB203580 slightly suppressed plasma clot retraction.</p><p><strong>Conclusion: </strong>PRP containing 0.5 mmol/L Ca2 <sup>+</sup> and 40×10<sup>9</sup>/L platelets can be induced with 0.2 U/ml thrombin to conduct plasma clot retraction analysis, which can be used to study the regulation of platelet function and evaluate the modulatory effects of drugs on plasma clot retraction.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Study on the Experimental Methodology of Plasma Clot Retraction].\",\"authors\":\"Yang-Gan Luo, Zi-Han Lu, Han-Jing Liao, Dou-Dou Hao, Man-Jing Huang, Zhi-Xiang Zhu\",\"doi\":\"10.19746/j.cnki.issn.1009-2137.2024.04.045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To explore the key factors affecting plasma clot retraction and optimize the experimental method of plasma clot retraction, in order to study the regulation of platelet function and evaluate the modulatory effects of drugs on plasma clot retraction.</p><p><strong>Methods: </strong>The effects of different concentrations of thrombin, Ca2 <sup>+</sup> and platelets on plasma clot retraction were studied, and the detection system of plasma clot retraction was optimized. The availability of the detection system was then validated by analyzing the regulatory effects of multiple signaling pathway inhibitors on plasma clot retraction.</p><p><strong>Results: </strong>Through the optimization study of multiple factors, platelet rich plasma (PRP) containing 0.5 mmol/L Ca2 <sup>+</sup> and 40×10<sup>9</sup>/L platelets was treated with 0.2 U/ml thrombin to perform plasma clot retraction analysis. After treatment with thrombin for 15 min, plasma clot retracted significantly. After treatment with thrombin for 30 min, the percentage of plasma clot retraction was more than 50%. The regulatory effects of multiple signaling pathway inhibitors on plasma clot retraction were studied in this detection system. PKC inhibitor Go 6983 exhibited a significant inhibitory effect on plasma clot retraction, while PI3K inhibitor Ly294002 and p38 MAPK inhibitor SB203580 slightly suppressed plasma clot retraction.</p><p><strong>Conclusion: </strong>PRP containing 0.5 mmol/L Ca2 <sup>+</sup> and 40×10<sup>9</sup>/L platelets can be induced with 0.2 U/ml thrombin to conduct plasma clot retraction analysis, which can be used to study the regulation of platelet function and evaluate the modulatory effects of drugs on plasma clot retraction.</p>\",\"PeriodicalId\":35777,\"journal\":{\"name\":\"中国实验血液学杂志\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国实验血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.04.045\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.04.045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的探讨影响血浆凝块回缩的关键因素,优化血浆凝块回缩的实验方法,从而研究血小板功能的调控,评价药物对血浆凝块回缩的调节作用:方法:研究不同浓度凝血酶、Ca2+和血小板对血浆凝块牵拉的影响,并优化血浆凝块牵拉的检测系统。然后通过分析多种信号通路抑制剂对血浆凝块回缩的调控作用,验证了检测系统的可用性:通过多因素优化研究,用 0.2 U/ml 凝血酶处理含有 0.5 mmol/L Ca2 + 和 40×109/L 血小板的富血小板血浆(PRP),进行血浆凝块回缩分析。凝血酶处理 15 分钟后,血浆凝块明显回缩。凝血酶处理 30 分钟后,血浆凝块回缩率超过 50%。该检测系统研究了多种信号通路抑制剂对血浆凝块回缩的调节作用。PKC 抑制剂 Go 6983 对血浆凝块回缩有明显的抑制作用,而 PI3K 抑制剂 Ly294002 和 p38 MAPK 抑制剂 SB203580 对血浆凝块回缩有轻微抑制作用:结论:用0.2 U/ml凝血酶诱导含0.5 mmol/L Ca2 +和40×109/L血小板的PRP进行血浆凝块回缩分析,可用于研究血小板功能调控和评估药物对血浆凝块回缩的调节作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Study on the Experimental Methodology of Plasma Clot Retraction].

Objective: To explore the key factors affecting plasma clot retraction and optimize the experimental method of plasma clot retraction, in order to study the regulation of platelet function and evaluate the modulatory effects of drugs on plasma clot retraction.

Methods: The effects of different concentrations of thrombin, Ca2 + and platelets on plasma clot retraction were studied, and the detection system of plasma clot retraction was optimized. The availability of the detection system was then validated by analyzing the regulatory effects of multiple signaling pathway inhibitors on plasma clot retraction.

Results: Through the optimization study of multiple factors, platelet rich plasma (PRP) containing 0.5 mmol/L Ca2 + and 40×109/L platelets was treated with 0.2 U/ml thrombin to perform plasma clot retraction analysis. After treatment with thrombin for 15 min, plasma clot retracted significantly. After treatment with thrombin for 30 min, the percentage of plasma clot retraction was more than 50%. The regulatory effects of multiple signaling pathway inhibitors on plasma clot retraction were studied in this detection system. PKC inhibitor Go 6983 exhibited a significant inhibitory effect on plasma clot retraction, while PI3K inhibitor Ly294002 and p38 MAPK inhibitor SB203580 slightly suppressed plasma clot retraction.

Conclusion: PRP containing 0.5 mmol/L Ca2 + and 40×109/L platelets can be induced with 0.2 U/ml thrombin to conduct plasma clot retraction analysis, which can be used to study the regulation of platelet function and evaluate the modulatory effects of drugs on plasma clot retraction.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
中国实验血液学杂志
中国实验血液学杂志 Medicine-Medicine (all)
CiteScore
0.40
自引率
0.00%
发文量
7331
期刊介绍:
期刊最新文献
[Clinical Analysis of Epstein-Barr Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation]. [Clinical Analysis of PD-1 Inhibitor Combined with Lenalidomide in Treatment of Relapsed CD5+ Diffuse Large B-Cell Lymphoma]. [Clinical Characteristics Analysis of EBV-associated Hemophagocytic Lymphohistiocytosis Patients with Acute Kidney Injury]. [Clinical Characteristics and Prognosis of Myelodysplastic Syndromes Patients with RUNX1 Gene Mutation]. [Clinical Characteristics and Prognosis of Patients with Primary Bone Marrow Lymphoma].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1